MIT’s new ‘recursive’ framework lets LLMs process 10 million tokens without context rot

While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...
eWeek

MIT Just Solved AI’s Memory Problem (And It’s Brilliantly Simple)

MIT’s Recursive Language Models rethink AI memory by treating documents like searchable environments, enabling models to ...

Vibrant’s New Title Empowers Emerging Developers With the Foundations of Efficient, Real-World Programming

Author Shawn Peters blends clarity and rigor to make data structures and algorithms accessible to all learners. COLORADO, CO, UNITED STATES, January 2, 2026 /EINPresswire.com/ — Vibrant Publishers ...
Daily Excelsior

Machine Learning Methods Used for Portfolio Optimization and Risk Management

Machine learning is reshaping the way portfolios are built, monitored, and adjusted. Investors are no longer limited to ...
InfoQ

MIT's Recursive Language Models Improve Performance on Long-Context Tasks

Researchers at MIT's CSAIL published a design for Recursive Language Models (RLM), a technique for improving LLM performance ...
pharmaphorum

Company Profile: Recursion

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
pharmaphorum

Recursion, Exscientia, and AI drug discovery’s moment of truth

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
The Motley Fool

Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
Insider Monkey

Here’s What J.P. Morgan Thinks About Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best High Volume Penny Stocks to Buy. On December 17, Priyanka Grover from J.P. Morgan upgraded Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ...